Militia Long/Short Equity ETF(ORR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ORR Militia Long/Short Equity ETF

盘前交易 10-08 07:12:55 EDT

38.25

-0.07

-0.18%

最高38.25	最低37.72	成交量4.43万
今开37.72	昨收38.32	日振幅1.40%
总市值3.46亿	流通市值3.46亿	总股本904.00万
成交额169.05万	换手率0.49%	流通股本904.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.25,"timestamp":1791403200000,"preClose":38.32,"halted":0,"volume":44346,"delay":0,"changeRate":-0.0018267223382046002,"floatShares":9040000,"shares":9040000,"eps":0,"marketStatus":"盘前交易","change":-0.07,"latestTime":"10-08 07:12:55 EDT","open":37.715,"high":38.253,"low":37.715,"amount":1690530.71748,"amplitude":0.01404,"askPrice":42.33,"askSize":100,"bidPrice":38.08,"bidSize":5,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791466200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":38.25,"sharesOutstanding":12720000,"nav":38.36,"aum":346774400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.25,"preClose":38.25,"latestTime":"17:29 EDT","volume":66,"amount":2516.5305,"timestamp":1791408567908,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.577393304632001,"impliedVol":0.2374,"impliedVolPercentile":0.836},"requestUrl":"/m/hq/s/ORR","defaultTab":"news","newsList":[{"id":"2669116157","title":"交易员：布雷曼讲话引发空头回补，纽元兑美元上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2669116157","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669116157?lang=zh_cn&edition=full","pubTime":"2026-09-22 14:11","pubTimestamp":1790057471,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CLSE","ORR","SHRT","UDN","WTLS","PRMN","UUP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669515363","title":"EGFR ex20ins赛道进入冲刺赛：伏美替尼申报一线适应症 国产双药同台竞技","url":"https://stock-news.laohu8.com/highlight/detail?id=2669515363","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669515363?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:19","pubTimestamp":1789975140,"startTime":"0","endTime":"0","summary":"迪哲医药的舒沃替尼、艾力斯的伏美替尼两大国产明星靶向药相继突破，国内EGFR ex20ins治疗格局有望改写。伏美替尼入局20ins一线审批国产双药同台竞技创新药赛道的竞争，本质是时间的竞争。依托WU-KONG28研究的重磅阳性结果，舒沃替尼一线EGFR ex20ins适应症上市申请于2026年5月正式获NMPA受理，并同步纳入优先审评程序。整体来看，2026年底至2027年，国内EGFR ex20ins一线赛道或将迎来双药集中获批的关键窗口期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-21/doc-inisqkzy8948524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PFS","ORR","BK4195","BK4211","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658657","title":"港股异动 | 映恩生物-B涨超9%，DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658657","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667658657?lang=zh_cn&edition=full","pubTime":"2026-09-14 14:38","pubTimestamp":1789367907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超9%，截至发稿，涨8.48%，报183港元，成交额1.65亿港元。消息面上，世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC BNT324/DB-1311联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期数据：截至2026年7月7日，71例可评估小细胞肺癌患者整体客观缓解率为70.4%，其中一线92.3%、二线77.3%、三线及以上52.4%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495543.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物 DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HK0000252152.HKD","BK1161","09606","HK0000500386.USD","LU2543165471.USD","KCAI","ORR","VXUS","BK4585","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666798529","title":"创新药将迎数据催化窗口！OS、PFS、ORR还都分不清楚？速查指南来了！收藏备用","url":"https://stock-news.laohu8.com/highlight/detail?id=2666798529","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666798529?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:22","pubTimestamp":1789125720,"startTime":"0","endTime":"0","summary":"创新药重磅提示！就在周六，2026年WCLC将正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司将公布旗下核心产品临床数据。III期达到终点，意味着获批概率大幅提升，属于实质性大利好。临床试验中通常报告“中位OS”，即50%患者存活的时间。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。以优效性为目标的头对头试验证据级别最高。权重数据截至2026.8.31。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhrw8907408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","LNGR","ORR","MEDX","159992","BK1574","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666583697","title":"迪哲医药：比瑞替尼II期研究发表，ORR达47.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666583697","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666583697?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:48","pubTimestamp":1788940107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660047782","title":"减持警报暂解？亿万富翁沃尔特质押Carvana(CVNA.US)股份 空头回补推动股价反弹逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660047782","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660047782?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:06","pubTimestamp":1787191592,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CLIX","BK4548","CLSE","LU0289960550.SGD","ORR","PRMN","SHRT","LU0175139822.USD","IE00BD6J9T35.USD","WTLS","BK4214","LU0133085943.USD","BK4588","CVNX","BK4503","BK4585","CVNY","CVNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657280621","title":"SpaceX解禁后两日暴涨23%，期权成交创纪录，空头回补或进一步推升股价","url":"https://stock-news.laohu8.com/highlight/detail?id=2657280621","media":"华尔街见闻","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657280621?lang=zh_cn&edition=full","pubTime":"2026-08-08 06:48","pubTimestamp":1786142899,"startTime":"0","endTime":"0","summary":"SpaceX两日市值激增3270亿美元，股价重新逼近135美元IPO发行价。周五截至纽约时间下午1时50分，SpaceX期权成交量达到224万份合约，其中看涨期权成交量达到130万份，创历史新高。目前仍有超过2.5亿股SpaceX股票被卖空，股价快速上涨，空头被迫回补可能进一步推升股价。","market":"nz","thumbnail":"https://static.tigerbbs.com/f16a7a67d0d2e6f1e72c43b8fe10d226","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f16a7a67d0d2e6f1e72c43b8fe10d226"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6c5b1e98ab57449e9a363569b6b7313b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3778979","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"SpaceX解禁后两日暴涨23%，期权成交创纪录，空头回补或进一步推升股价","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNK","SPCG","LU2360107168.USD","SPCF","LU1861559042.SGD","WSPC","SPCH","DXYZ","LU1861220033.SGD","SPAL","ORBX","UFO","SSPC","SPCQ","WTLS","XOVR","LOFF","SPCX","LU1861215975.USD","SPCU","PRMN","SPAX","CLSE","LU1861558580.USD","WARP","MARS","ORR","LU2290526834.HKD","BK4089","SPCM","BK4615","SHRT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2657644945","title":"美股异动 | SpaceX(SPCX.US)涨逾8% 限售股解禁未现抛压 空头回补推动股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644945","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644945?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:26","pubTimestamp":1786112794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SPCF","DXYZ","SPAL","LU1861558580.USD","CLSE","SHRT","SPCG","ORBX","SPCU","WSPC","SPCX","WARP","SSPC","XOVR","BK4615","SPCQ","MARS","ORR","LU2290526834.HKD","SPCH","UFO","LU1861559042.SGD","LU1861215975.USD","BK4089","LOFF","SPAX","LU1861220033.SGD","LU2360107168.USD","SNK","WTLS","PRMN","SPCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656634286","title":"多家机构判断：中国新能源车空头回补仍将持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2656634286","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656634286?lang=zh_cn&edition=full","pubTime":"2026-08-03 10:55","pubTimestamp":1785725750,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["ORR","KBA","WTLS","CLSE","PRMN","SHRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656566349","title":"花旗：汽车股空头回补料持续 新能源汽车销量明显提升等利好支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2656566349","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656566349?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:39","pubTimestamp":1785717558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CARU","FDIS","BK4504","IE00BSNM7G36.USD","LU2125154778.USD","BK4585","LU0170899867.USD","ORR","LU0310800965.SGD","CLSE","BK4207","LU1244550494.USD","BK4559","LU0130517989.USD","LU1791807156.HKD","LU0072461881.USD","FTXO","LU0106831901.USD","IYF","SHRT","TFNS","LU1244550577.SGD","LU1267930227.SGD","LU2417539215.USD","LU0128525689.USD","BK4566","LU0648001328.SGD","LU2360032135.SGD","LU0320765646.SGD","BK4534","LU0980610538.SGD","LU1201861249.SGD","LU2125154935.USD","LU2236285917.USD","LU1244550221.USD","WTLS","LU1506573853.SGD","LU1074936037.SGD","LU0052756011.USD","LU0477156953.USD","LU0203347892.USD","PRMN","LU0098860793.USD","LU2456880835.USD","LU0162691827.USD","LU2462157665.USD","LU0203345920.USD","LU0314106906.USD","LU1162221912.USD","LU1366192091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656349565","title":"花旗预计，在新能源车批发销量显著提升、行业库存去化明显等利好推动下，中国汽车板块的空头回补势头将持续。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656349565","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656349565?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:38","pubTimestamp":1785717532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0170899867.USD","LU0106831901.USD","PRMN","LU1244550221.USD","SHRT","BK4585","LU0072461881.USD","LU0477156953.USD","LU0203345920.USD","BK4566","LU2462157665.USD","LU1366192091.USD","LU2236285917.USD","BK4207","LU0130102774.USD","LU0648001328.SGD","LU1267930227.SGD","LU1506573853.SGD","LU0128525689.USD","RTH","LU0980610538.SGD","LU2125154778.USD","LU1244550494.USD","LU1791807156.HKD","LU2456880835.USD","LU1074936037.SGD","LU0052756011.USD","LU2417539215.USD","WTLS","SUPL","BK4534","BK4588","LU0320765646.SGD","BK4559","CLSE","ORR","LU2360032135.SGD","LU1244550577.SGD","LU0098860793.USD","LU1201861249.SGD","TFNS","LU1162221912.USD","LU2125154935.USD","BK4504","IYF","LU0203347892.USD","LU1668664300.SGD","LU0162691827.USD","LU0314106906.USD","FTXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649617065","title":"日本橡胶期货受空头回补及非洲出口限制双重因素提振走高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617065","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649617065?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:38","pubTimestamp":1783305480,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ORR","CLSE","EFFE","PRMN","ION","SHRT","FTAG","RJA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921641","title":"核心管线数据利空 基石药业股价大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921641","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640921641?lang=zh_cn&edition=full","pubTime":"2026-06-03 07:00","pubTimestamp":1780441200,"startTime":"0","endTime":"0","summary":"6月1日盘前，基石药业（2616.HK）宣布核心资产CS2009（PD-1/VEGF/CTLA-4三特异性抗体）的多项关键临床进展，于美国临床肿瘤学会（ASCO）年会上通过两份壁报正式发布，涵盖一线及后线非小细胞肺癌（NSCLC）及结直肠癌（CRC）患者I/II期临床试验数据，以及晚期实体瘤患者更长随访后的成熟I期临床数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606033757998235.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606033757998235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0266512127.USD","BK4213","LU0456854461.SGD","ORR","CRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995293","title":"劲方医药-B公布GFH375治疗癌症疗效数据 ORR达40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995293","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640995293?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:14","pubTimestamp":1780362840,"startTime":"0","endTime":"0","summary":"6月2日，劲方医药-B（02595）发布公告，宣布其GFH375单药治疗KRASG12D突变型胆管癌和结直肠癌的初步疗效数据已于6月1日的ASCO年会上进行口头报告。报告显示，20名KRASG12D突变型胆管癌患者的总体客观缓解率（ORR）为40%，疾病控制率（DCR）为95%。在600mgQD（RP2D）剂量水平的18名患者中，ORR为44.4%，DCR为94.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606023756897496.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606023756897496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1161","ORR","02595","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640438958","title":"核心管线数据利空，基石药业股价大跌超32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640438958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640438958?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:05","pubTimestamp":1780308300,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明6月1日盘前，基石药业（2616.HK）宣布核心资产CS2009（PD-1/VEGF/CTLA-4三特异性抗体）的多项关键临床进展，于美国临床肿瘤学会（ASCO）年会上通过两份壁报正式发布，涵盖一线及后线非小细胞肺癌（NSCLC）及结直肠癌（CRC）患者I/II期临床试验数据，以及晚期实体瘤患者更长随访后的成熟I期临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013756146980.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013756146980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ORR","CRC","LU0456854461.SGD","LU0266512127.USD","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627491097","title":"核药“狂飙”：2026年中外巨头激战300亿美元蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2627491097","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627491097?lang=zh_cn&edition=full","pubTime":"2026-04-14 12:54","pubTimestamp":1776142440,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛2026年的春天，核药赛道没有一丝“倒春寒”的迹象。4月中旬，两则消息几乎同时引爆了全球核医学圈。一则是关于“中国原创”的崛起：百洋医药集团孵化企业瑞迪奥研发的99mTc-3PRGD2（吉伦泰）正式获批，这是全球首个用于SPECT显像的广谱肿瘤显像剂，打破了PET技术近30年的垄断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704207863.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704207863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["RDC","BK4161","HCC","ORR","BK4006","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518213795","title":"KRAS G12D先驱都扛不住了","url":"https://stock-news.laohu8.com/highlight/detail?id=2518213795","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518213795?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:17","pubTimestamp":1741594679,"startTime":"0","endTime":"0","summary":"热度持续攀升的KRAS G12D领域，却不断传出糟糕的消息。3月5日，据外媒消息，BMS已经放弃开发KRAS G12D抑制剂MRTX1133，原因是前景堪忧。这并非KRAS G12D赛道的第一个坏消息。如今，随着又一位重磅选手折戟，无疑给KRAS G12D领域敲响了警钟，尤其是对于处在跟随阶段的国内药企来说。很显然，这些国内跟随的选手需要进一步审视其KRAS G12D分子的结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/252604","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512794661","title":"东方亮，西方不亮：出海管线之殇","url":"https://stock-news.laohu8.com/highlight/detail?id=2512794661","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512794661?lang=zh_cn&edition=full","pubTime":"2025-02-19 17:18","pubTimestamp":1739956689,"startTime":"0","endTime":"0","summary":"海外的临床结果，能否达到中国早期试验的承诺？但很遗憾，结果并不是那么让人满意。最新给出回答的是Corbus Pharmaceuticals。在ASCO泌尿生殖系统癌症研讨会上，Corbus公布了引进自石药集团的Nectin-4 ADC CRB-70第一个西方临床结果。数据公布后，Corbus盘中股价跌幅一度超15%。在该消息的影响下，Elevation单日股价暴跌63.37%。石药集团在中国开展的1期临床，初步ORR是28%；而Corbus在海外开展的1期临床，初步ORR是27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/251165","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0072913022.USD","LU1226287875.USD","BK1191","LU1152091168.USD","IE00BZ08YS42.EUR","01093","LU0140636845.USD","LU1951186391.HKD","LU1993786604.SGD","LU1807302812.USD","ORR","IE0008368742.USD","BK1515","LU1008478684.HKD","LU0067412154.USD","LU0880133367.SGD","LU1152091754.HKD","LU1960683339.HKD","BK1521","IE0008369823.USD","SG9999004220.SGD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1226288253.USD","IE00B543WZ88.USD","LU1226287792.SGD","LU1226288170.HKD","LU1226287529.USD","IE00B031HY20.USD","LU0326950275.SGD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512142249","title":"DLL3领域的中国时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2512142249","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512142249?lang=zh_cn&edition=full","pubTime":"2025-02-17 16:37","pubTimestamp":1739781474,"startTime":"0","endTime":"0","summary":"DLL3靶点研究开发已有超20年历史，该领域的FIC药物安进的CD3/DLL3双抗tarlatamab也已经获批上市。中国药企再一次将DLL3靶点的研发，推向了新一轮高潮。2023年11月至今，DLL3领域共有6起超1亿美元的交易，中国药企贡献了3例。这场围绕DLL3靶点的争夺战，正在成为中国创新药崛起的缩影。在DLL3靶点研发领域，引领发展的是海外科学家。从再鼎医药的临床数据公布，再到恒瑞医药、信达生物的接连出海，证明了中国药企在DLL3 ADC领域的搅局能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/250965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ORR","IE00B7SZL793.SGD","IE00B19Z4B17.USD","LU2065731478.USD","IE0031619046.USD","CRS","IE00B66KJ199.SGD","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504212978","title":"信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新®（利厄替尼片）获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2504212978","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504212978?lang=zh_cn&edition=full","pubTime":"2025-01-17 08:00","pubTimestamp":1737072000,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月17日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司，与奥赛康药业今日联合宣布，第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物奥壹新的新药上市申请获中国国家药品监督管理局批准上市，用于既往经EGFR-TKI治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌成人患者治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"https://wwwold.prnasia.com/story/archive/4598259_ZH98259_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4598259_ZH98259_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK4195","BK4570","LU2328871848.SGD","BK1589","LU1969619763.USD","ORR","PFS","IVBIY","BK1583","BK4211","01801","LU2488822045.USD","PPI","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":-0.0239},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0135},{"period":"1year","weight":0.2205},{"period":"ytd","weight":0.1197}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"NASDAQ","name":"Militia Long/Short Equity ETF","nameEN":"Militia Long/Short Equity ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Militia Long/Short Equity ETF(ORR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Militia Long/Short Equity ETF(ORR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Militia Long/Short Equity ETF,ORR,Militia Long/Short Equity ETF股票,Militia Long/Short Equity ETF股票老虎,Militia Long/Short Equity ETF股票老虎国际,Militia Long/Short Equity ETF行情,Militia Long/Short Equity ETF股票行情,Militia Long/Short Equity ETF股价,Militia Long/Short Equity ETF股市,Militia Long/Short Equity ETF股票价格,Militia Long/Short Equity ETF股票交易,Militia Long/Short Equity ETF股票购买,Militia Long/Short Equity ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Militia Long/Short Equity ETF(ORR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Militia Long/Short Equity ETF(ORR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}